

ACTION REQUEST

Subject: Subcontract Agreement between the University of Michigan and ImBio, LLC

Action Requested: Authorization to enter into Agreement

Preamble:

A statutory conflict of interest situation was identified by the Office of Research and Sponsored Projects while reviewing the Proposal Approval Form which then triggered a review by the Medical School Conflict of Interest Board. A plan for management of the possible risks associated with the conflict of interest was then developed and approved by the Board and agreed to by the parties involved.

This proposed agreement ("Agreement") falls under the State of Michigan Conflict of Interest Statute because Professors Brian Ross and Alnawaz Rehemtulla are both employees of the University of Michigan ("University"), and partial owners of ImBio, LLC ("ImBio"). The law permits such an Agreement provided it is disclosed to the Board of Regents ("Regents") of the University of Michigan and approved in advance by a 2/3 vote.

Background:

Dr. Ross, a Professor in the Departments of Radiology and Biological Chemistry, and Dr. Rehemtulla, a Professor in the Department of Radiation Oncology, Medical School, are partial owners of a for-profit company called ImBio, LLC (the "Company"). The Company wishes to fund a National Institutes of Health (prime) SBIR Phase I & II project entitled: "CT Biomarker for BOS Assessment in Cancer Patients," (ORSP# 15-PAF03396) in the Department of Radiology under the direction of Dr. Craig Galban, Associate Professor of Radiology, Medical School and Associate Professor of Biomedical Engineering, College of Engineering. The purpose of this project is to develop and evaluate a CT-based imaging biomarker for commercialization that facilitates diagnosis of bronchiolitis obliterans syndrome (BOS) in patients treated with bone marrow transplantation.

Agreement Terms:

The terms of the Agreement conform to University policy. The period of performance for the project is approximately three and a half (3 ½) years. The amount of funding support will not exceed one million ninety-nine thousand five hundred and thirty-five dollars (\$1,099,535). Since research projects are often amended, this agreement includes provisions for changes in time, amount, and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

Impact of the Agreement

The Agreement will support an effort by Dr. Galban to use his expertise and University laboratory, as well as other University resources to assist in the development of a commercial software platform that will analyze paired inspiration and expiration whole-lung CT data using a modified Parametric Response Mapping (PRM) technique as well as validate PRM as an early biomarker of bronchiolitis obliterans syndrome (BOS).

Recommendations:

This matter has been reviewed and approved by the Medical School Conflict of Interest Board. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University's entering into this Agreement with ImBio, LLC.

Respectfully submitted,



S. Jack Hu
Interim Vice President for Research

February 2015